Magnetic resonance-guided focused ultrasound for the treatment of tremor.
Kazuaki YamamotoCan SaricaAaron LohArtur VetkasNardin SamuelVanessa MilanoAjmal ZemmarJurgen GermannCletus CheyuoAlexandre BoutetGavin Jb EliasHisashi ItoTakaomi TairaAndres M LozanoPublished in: Expert review of neurotherapeutics (2022)
Essential tremor (ET) has been the major indication for MRgFUS since a milestone randomized controlled trial (RCT) in 2016, with substantial evidence attesting to the efficacy and acceptable safety profile of this treatment. Patients with other tremor etiologies are also being treated with MRgFUS, with studies - including an RCT - suggesting parkinsonian tremor in particular responds well to this intervention. Additionally, targets other than the ventral intermediate nucleus, such as the subthalamic nucleus and internal segment of the globus pallidus, have been reported to improve parkinsonian symptoms beyond tremor, including rigidity and bradykinesia. Although MRgFUS is encumbered by certain unique technical challenges, it nevertheless offers significant advantages compared to alternative neurosurgical interventions for tremor. The fast-growing interest in this treatment modality will likely lead to further scientific and technological advancements that could optimize and expand its therapeutic potential.